‘7+3’ (7 days of cytarabine overlapping with 3 of daunorubicin or idarubicin) is probably the most commonly used remission induction regimen in adults aged ⩽60 with untreated AML. Cooperative group ...
Please provide your email address to receive an email when new articles are posted on . Less than 5% of adults with thyroid eye disease who completed a full course of teprotumumab required a second ...
The infectious disease expert says he started suffering COVID symptoms again and is taking a second course of Paxlovid Amanda Taheri is an editorial intern at PEOPLE. She is a graduate student in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results